Clinical trials were significantly disrupted by COVID-19 but research from Annals of Oncology indicates patient accruals and trial activations have returned to higher than normal levels. Dana-Farber’s Chris Labaki, MD, & Brigham and Women’s Ziad Bakouny, MSc, MD, detail the results. Press release: https://www.dana-farber.org/newsroom/news-releases/2022/cancer-clinical-trials-bounce-back-after-significant-covid-19-disruption--data-from-two-large-us-cancer-centers/
Video published 7/19/22